<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92710</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Narushenie balansa aminokislot pri pechenochnoy nedostatochnosti i ego rol' v razvitii pechenochnoy entsefalopatii</article-title><trans-title-group xml:lang="ru"><trans-title>Нарушение баланса аминокислот при печеночной недостаточности и его роль в развитии печеночной энцефалопатии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shul'pekova</surname><given-names>Yu. O</given-names></name><name xml:lang="ru"><surname>Шульпекова</surname><given-names>Ю. О</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ГОУ ВПО Московская медицинская академия им. И.М.Сеченова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2008-08-15" publication-format="electronic"><day>15</day><month>08</month><year>2008</year></pub-date><volume>10</volume><issue>8</issue><issue-title xml:lang="en">VOL 10, NO8 (2008)</issue-title><issue-title xml:lang="ru">ТОМ 10, №8 (2008)</issue-title><fpage>58</fpage><lpage>62</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2008, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2008, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2008</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/92710">https://consilium.orscience.ru/2075-1753/article/view/92710</self-uri><abstract xml:lang="ru"><p>Главной задачей лечения печеночной энцефалопатии служит снижение выработки аммиака в организме и стимуляция процесса его выведения. С этой целью принято назначать лактулозу, антибиотики, орнитин-аспартат. На практике нередко приходится сталкиваться с тем, что больные в состоянии печеночной энцефалопатии в качестве основного и явно недостаточного источника энергии получают инфузии 5–10% раствора глюкозы в объеме 1–1,5 л, а количество "разрешенного" белка не превышает 20 г в день. В общей сложности такое "питание" обеспечивает 400–600 ккал/сут, что явно недостаточно. Как ни парадоксально, но наше "лечение" может усугублять трофологические расстройства у больного. Решение вопроса о безвредной дозе белка у пациентов с рецидивирующей энцефалопатией, безусловно, требует обдуманного подхода, поскольку существует категория больных с плохой переносимостью белка. Однако и в таких случаях их ежедневный рацион в "светлые промежутки" должен содержать не менее 40 г белка, преимущественно растительного происхождения.</p></abstract></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Berry H.K, Brunner R.L, Hunt M.M et al. Valine, isoleucine, and leucine. A new treatment for phenylketonuria. Am J Dis Child 1990; 144: 539–43.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Blomstrand E, Hassmen P, Ek S et al. Influence of ingesting a solution of branched - chain amino acids on perceived exertion during exercise. Acta Physiol Scand 1997; 159: 41–9.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Blomstrand E, Hassmen P, Ekblom B et al. Administration of branched - chain amino acids during sustained exercise – effects on performance and on plasma concentration of some amino acids. Eur J Appl Physiol 1991; 63: 83–8.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Charlton M. Branched-Chain Amino Acid Enriched Supplements as Therapy for Liver Disease. J Nutr 2006; 136: 295S–8S.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Chin S.E, Sheperd R.W, Thomas B.J et al. Nutritional support in children with end - stage liver disease: a randomized crossover trial of a branched - chain amino acid supplement. Am J Clin Nutr 1992; 56: 158–63.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Egberts E-H, Schomerus H, Hamster W, Jurgens P. Branched chain amino acids in the treatment of latent portosystemic encephalopathy. Gastroenterol 1985; 88: 887–95.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Greer B.K, Woodard J.L, White J.P et al. Branched - chain amino acid supplementation and indicators of muscle damage after endurance exercise. Int J Sport Nutr Exerc Metab 2007; 17 (6): 595–607.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hassmеn P, Blomstrand E, Ekblom B, Newshomle E.A. Branched - chain amino acid supplementation during 30-km competitive run: mood and cognitive performance. Nutrition 1994; 10: 405–10.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Plaitakis A, Smith J, Mandeli J et al. Pilot trial of branched - chain amino acids in amyotrophic lateral sclerosis. Lancet 1988; 1015–20.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Maddrey W.C. Branched chain amino acid therapy in liver disease. J Am Coll Nutr 1985; 4: 639–50.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Naylor C.D, O\'Rourke K, Detsky A.S et al. Parenteral nutrition with branched - chain amino acids in hepatic encephalopathy. A meta - analysis. Gastroenterology 1989; 97: 1033–42.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kato M, Miwa Y, Tajika M et al. Preferential use of branched - chain amino acids as an energy substrate in patients with liver cirrhosis. Internal Med 1998; 37: 429–34.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kawaguchi T, Nagao Y, Matsuoka H et al. Branched - chain amino acid - enriched supplementation improves insulin resistance in patients with chronic liver disease. Int J Mol Med 2008; 22 (1): 105–12.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>O\'Keffe S.J.D, El-Zayadi A, Carraher T et al. Malnutrition and immune competence in patients with liver disease. Lancet 1980; ii: 615–7.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>O\'Keffe S.J.D, Abraham R, El-Zayadi A et al. Increased plasma tyrosine concentrations in patients with cirrhosis and fulminant hepatic failure associated with increased plasma tyrosine flux and reduced hepaic oxidation capacity. Gastroenterology 1981; 81: 1014–24.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Silk D B Branched chain amino acids in liver disease: fact or fantasy? Gut 1986; 27 (Suppl. 1): 103–10.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Soreide E, Skeie B, Kirvela O et al. Branched - chain amino acid in chronic renal failure atients: respiratory and sleep effects. Kidney Int 1991; 40: 539–43.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Wahren J, Denis J, Desurmont P et al. Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study. Hepatology 1983; 3 (4): 475–80.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Young V.R, Bier D.M, Pellett P.L. A theoretical basis for increasing current estimates of the amino acid requirements in adult man, with experimental support. Am J Clin Nutr 1989; 50: 80–92.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Zello G.A, Wykes L.F, Ball R.O et al. Recent advances in methods of assessing dietary amino acid requirements for adult humans. J Nutr 1995; 125: 2907–15.</mixed-citation></ref></ref-list></back></article>
